Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Camolyn, Fisiolin drops recalled

This article was originally published in The Tan Sheet

Executive Summary

U.S. Ofthalmi recalls certain lots of 15 mL bottles of OTC Camolyn eye drops and Fisiolin nasal drops nationwide because it cannot guarantee product sterility. The Hallandale, Fla., firm said non-sterile products can cause infection, and while the chances of a serious adverse reaction are "remote," the company "is taking a conservative approach," according to an April 7 FDA release No adverse effects have been reported. The firm withdraws lots of Camolyn Homeopathic, Camolyn Plus, Naphazoline + Chamomile 15 mL, Camolyn Refresh 15 mL, Camolyn-A, Naphazoline + Pheniramine 15 mL and Fisiolin Nasal Drops Sodium Chloride Pediatric Uses 15 mL

You may also be interested in...



Horizon Teprotumumab's US Advisory Cmte. Likely To Focus On Labeling, Not Approval, Questions

FDA seems poised to approve the drug for the orphan eye disease called TED, but remains concerned about labeling for some adverse events.

Introducing The Citeline Awards 2020; Nominations Open

The 2020 Citeline Awards, Informa’s premier event recognizing excellence in R&D, recognize the myriad achievements across the industry and are open for nominations through 17 January.

US FDA Puts Spotlight On Alkermes' Violative Vivitrol Ad

The apparently first-ever FDA press release for an advertising warning letter underscores importance of opioid issues – and the agency’s changing approach to media relations in general. FDA objects to Alkermes journal ad that excludes risk information about its opioid dependence treatment drug.

Topics

UsernamePublicRestriction

Register

PS103981

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel